Risk Management Could Bolster FDA Behind-The-Counter Switches – Gottlieb
This article was originally published in The Tan Sheet
Executive Summary
FDA's authority to require behind-the-counter sale and other restrictions for some nonprescription switches is strengthened by risk-management provisions of "FDA Revitalization" bills pending in Congress, according to former FDA Deputy Commissioner Scott Gottlieb
You may also be interested in...
Phantom Stopgap PDUFA Renewal Might Prompt Faster FDARA Action
A proposal apparently circulated by House Democratic leaders to renew user fee programs for three months while negotiations on FDA reform legislation continue is "not an option," Sen. Michael Enzi, R-Wyo., ranking member of the Health, Education, Labor and Pensions Committee, has declared
Phantom Stopgap PDUFA Renewal Might Prompt Faster FDARA Action
A proposal apparently circulated by House Democratic leaders to renew user fee programs for three months while negotiations on FDA reform legislation continue is "not an option," Sen. Michael Enzi, R-Wyo., ranking member of the Health, Education, Labor and Pensions Committee, has declared
FDA Works On Removing Risk From Understanding RiskMAPs Program
Stakeholders' misperceptions about FDA's Risk Minimization Action Plans program have prompted the agency to consider how to provide clarity, including creating a Web site that will serve as a central source of risk-management plan information